Abstract of COGEM advisory reports on the application for a clinical trial testing recombinant Vaccinia virus- en Fowlpox virus- vaccine in patients with prostate cancer

Advisory reports | 26.09.2013 | CGM/130926-01

In the Netherlands recently an application was filed for a clinical trial entitled “A randomized double-blind, phase 3 efficacy trial of PROSTVAC GM-CSF in men with asymptomatic or minimally metastatic, castrate-resistant prostate cancer’. The trial in the Netherlands is part of a multicenter trial and similar applications are most likely filed in Australia, Belgium, Canada, Estonia, France Germany, Poland, Spain, Iceland and Great Britain. In order to give other advisory bodies and environmental risk-assessors insight in the considerations and opinion of the COGEM, an abstract in English was made available.

Download publication